Ignacio Jesús Dávila González

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended granting marketing authorisation in the European Union for Eurneffy (epinephrine), the first nasally administered medicine for the emergency treatment of allergic reactions. Anaphylaxis is the most severe form of allergic reaction that can occur within minutes of exposure to an allergen and can be life-threatening. Until now, treatment with epinephrine (also known as adrenaline) to reduce the anaphylactic reaction is done by intramuscular injection. 

Two teams of researchers have separately described a population of memory lymphocytes that may be responsible for the persistence of allergies over time. The work has analysed responses to allergens such as those present in peanuts, dust and birch. According to the authors, whose research is published in Science Translational Medicine, these cells could serve as a target for the treatment of various types of allergies.